Note: You are seeing this message either because your browser has not loaded our stylesheets, or because your browser does not support stylesheets (CSS). Please upgrade to a relatively modern browser to improve your experience. Not sure what to upgrade to? Try Firefox.
The Science Advisory Board
Screen Name: 
 
Password: 
 

SAB News

Winner of the "Tools and Techniques of Neuroscience" Study Announced
Posted 7/27/2005

While multiple types of DNA sequence variations exist, single nucleotide polymorphisms (SNPs) are the most frequent form of mutation in many genes. Because of their abundance and stability, SNPs are used in a variety of biologic, genetic, and pharmacologic applications. In order to benchmark the current state of SNPs technologies, The Science Advisory Board (SAB) assessed researchers’ experimental parameters, sample throughput levels and genotyping methods. In this study, the Board also queried its members about improvements to SNP genotyping that would most benefit researchers as well as the challenges of integrating genotyping and pharmacogenomics into clinical practice. Over 500 scientists participated in this study, and a summary of their best practices and insights is presented in the SAB "Study Snapshots" webpage.

As a token of our appreciation, study participants were entered in an additional drawing for a $20 gift certificate from Amazon.com.

We are excited to announce that Karen, a Principal Investigator from the United States, was the contest winner.

When asked to provide a comment to the following question, "Where do you see your SNP genotyping research in the continuum of bringing personalized medicine into reality?," Karen replied:

"SNP genotyping research, particularly epigenetics, has the potential for not only evaluating individual (not just population) disease risk, but also the power to predict responsiveness to therapeutics, and in the case of epigenetic changes, has value for monitoring of individual patients' treatment responses and the customization of personalized medical treatment plans. Epigenetics may lead to far more accurate assessment of patient prognosis, as well as the design of more effective therapeutics to target particular regulatory gene networks."

SAB Member comments to the bonus question have been posted on The SAB Web site and can be reviewed by accessing the study's Insights page.

Congratulations to everyone who made this study possible.

The Science Advisory Board provides opportunities for its members to earn honoraria each and every time they participate in SAB-sponsored studies. Interested in finding out more? Please visit: http://www.scienceboard.net/about/participate.asp.

Scientific & Medical
Experts Needed!

The Science Advisory Board is the world's most established network of life scientists!

Voice your opinions on companies, products, protocols and even humor in a lively, real-time, interactive Online Community of over 41,000 life science & medical professionals.

Redeem generous rewards for participation in studies, contributing website content and referring colleagues.

Join Right Now!
(It's Free!)

Search This Site
only search scienceboard.net
only search Forums
What's this?